Challenges in the discovery and development of new agents for the treatment of obesity

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 5, 2007, Pages 753-755

  Staten, M A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCOMPLIA; AMINOREX; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEVELOPMENT; HEART VALVE; HUMAN; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIDE EFFECT;

ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS; DRUG DESIGN; HISTORY, 20TH CENTURY; HUMANS; OBESITY;

EID: 34247211701     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100161     Document Type: Article

References (16)

1. Mokdad, A.H., Serdula, M.K., Dietz, W.H., Bowman, B.A., Marks, J.S. & Koplan, J.P. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 282, 1519-1522 (1999).
2. Olshansky, S.J. et al. A potential decline in life expectancy in the United States in the 21st century. New Engl. J. Med. 352, 1138-1145 (2005).
3. Puhl, R. & Brownell, K.D. Bias, discrimination, and obesity. Obesity Res. 9, 788-805 (2001).
4. Price, J.H., Desmond, S.M., Krol, R.A., Snyder, F.F. & O'Connell, J.K. Family practice physicians' beliefs, attitudes, and practices regarding obesity. Am. J. Prev. Med. 3, 339-345 (1987).
5. Foster, G.D., Wadden, T.A., Vogt, R.A. & Brewer, G. What is a reasonable weight loss? Patient's expectations and evaluations of obesity treatment outcomes. J. Consul. Clin. Psychol. 65, 79-85 (1997).
6. Weintraub, M. Long-term weight control: The National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin. Pharmacol. Ther. 51, 586-594 (1992).
7. Weintraub, M. et al. Long-term weight control study I (weeks 0 to 34). Clin. Pharmacol. Ther. 51, 586-594 (1992).
8. Weintraub, M. et al. Long-term weight control study II (weeks 34 to 104). Clin. Pharmacol. Ther. 51, 595-601 (1992).
9. Weintraub, M., Sundaresan, P.R., Schuster, B., Moscucci, M. & Stein, E.C. Long-term weight control study III (weeks 104 to 156). Clin. Pharmacol. Ther. 51, 602-607 (1992).
10. Weintraub, M. et al. Long-term weight control study IV (weeks 156 to 190). Clin. Pharmacol. Ther. 51, 608-614 (1992).
11. Weintraub, M., Sundaresan, P.R., Schuster, B., Averbuch, M., Stein, E.C. & Byrne, B.A. Long-term weight control study V (weeks 190 to 210). Clin. Pharmacol. Ther. 51, 615-618 (1992).
12. Connolly, H.M. et al. Valvular heart disease associated with fenfluramine-phentermine. New Engl. J. Med. 337, 581-588 (1997).
13. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L. & Friedman, J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994).
14. Shillingford, C.A. & Vose, C.W. Effective decision-making: progressing compounds through clinical development. Drug Discov. Today 6, 941-946 (2001).
15. Heymsfield, S.B. et al. Recombinant leptin for weight loss in obese and lean adults. A randomized, controlled, dose-escalation trial. JAMA 282, 1568-1575 (1999).
16. Davidson, M.H. et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 281, 235-242 (1999).